Editorial: Molecular Network Study of Pituitary Adenomas

The use of mass spectrometry in a proteome‐centered multiomics study of human pituitary adenomas

“…For example, multiomics data are obtained with second‐ and third‐generation sequencing technologies (Helicos BioSciences, Roche/454, Life/APG, Illumina/Solixa, PacBio RS, and Oxford Nanopore sequencing), hybridization‐ or sequence‐based microarrays, RNA‐seq, one‐dimensional gel electrophoresis (1DGE), two‐dimensional gel electrophoresis (2DGE), two‐dimensional difference in‐gel electrophoresis (2D‐DIGE), liquid chromatography with tandem mass spectrometry (LC‐MS/MS), NMR spectroscopy, chromatography coupled to MS, laser‐capture microdissection (LCM), single‐cell sequence, CT, PET/CT, and MRI (Lu & Zhan, 2018). The integration of such a diverse array of structural information and ‐omics data significanly improves our understanding of molecular mechanisms in PAs, and accelerates the development of PA treatment with PPPM (Zhan & Desiderio, 2020) (Figure 1).…”

“…Multiomics is an effective technological approach to study the complex PAs from the systems view. A multiomics, data‐derived, signaling pathway network effectively helps to clarify molecular mechanisms, discover new multitarget therapeutic targets/drugs, and identify effective and reliable pattern biomarkers for PPPM and PM practice in PAs (Zhan & Desiderio, 2020). Some multiomics‐based signaling pathway networks, molecular network‐based pattern biomarkers, and therapeutic targets have been discovered.…”

“…One must consider a complex tumor such as a pituitary tumor within the framework of a multiparameter systematic model that includes molecular alterations at the level of DNA, RNA, protein, peptide, metabolites, and imaging features—all within an altered network system (Zhan et al, 2016; Zhan & Desiderio, 2020).…”

“…The complex biological data derived from multiple “omics” of PAs could provide system information and molecular network information that can accurately pinpoint relevant novel biomarkers, potential molecular mechanisms, and reliable therapeutic targets for PA patients (Zhan & Desiderio, 2020). By combining these omics diagnostic and therapeutic biomarkers provide a close relationship among the structure, physiology, and pathology in PAs (Li & Zhan, 2019).…”

Introductory Chapter: Proteoforms

“…Further, each proteoform is involved in a molecular network system and has multiple PTMs. It is the research hot spot how different PTMs competitively or synergistically affect proteoform structure and functions and their involved molecular network system [20][21][22][23][24]. Molecular network-based proteoform pattern biomarkers will have more important scientific merits.…”